Posted by Michael Wonder on 10 Dec 2022
Janssen submits biologics license application to US FDA for talquetamab for the treatment of patients with relapsed or refractory multiple myeloma
9 December 2022 - Janssen today announced the submission of a biologics license application to the US FDA for talquetamab for the treatment of patients with relapsed or refractory multiple myeloma.
Talquetamab is an investigational, off-the-shelf (ready to use), bispecific T-cell engager antibody targeting both GPRC5D, a novel drug target that is on some normal cells but over-expressed on myeloma cells, and separately targets CD3 on T cells.
